Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study to Evaluate the Efficacy and Safety of an Adjuvant Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With HER2 Low Breast Cancer (Cornerstone-001)

NCT05163223 is registered in ClinicalTrials.gov with Aston Sci. Inc. as lead sponsor.

NCT NCT05163223
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05163223 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study to Evaluate the Efficacy and Safety of an Adjuvant Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With HER2 Low Breast Cancer (Cornerstone-001)
Lead sponsor
Aston Sci. Inc.
Phase
Phase 2
Overall status
Terminated
Start date
February 28, 2022
Completion date
May 31, 2024
Enrollment
10 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer